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Omega-6 (n-6) polyunsaturated fatty acids (PUFA) (e.g., arachidonic acid (AA)) and omega-3 (n-3) PUFA (e.g., eicosapentaenoic
acid (EPA)) are precursors to potent lipid mediator signalling molecules, termed “eicosanoids,” which have important roles in the
regulation of inﬂammation. In general, eicosanoids derived from n-6 PUFA are proinﬂammatory while eicosanoids derived from
n-3 PUFA are anti-inﬂammatory. Dietary changes over the past few decades in the intake of n-6 and n-3 PUFA show striking
increases in the (n-6) to (n-3) ratio (∼15:1), which are associated with greater metabolism of the n-6 PUFA compared with n-
3 PUFA. Coinciding with this increase in the ratio of (n-6):(n-3) PUFA are increases in chronic inﬂammatory diseases such as
nonalcoholic fatty liver disease (NAFLD), cardiovascular disease, obesity, inﬂammatory bowel disease (IBD), rheumatoid arthritis,
and Alzheimer’s disease (AD). By increasing the ratio of (n-3):(n-6) PUFA in the Western diet, reductions may be achieved in the
incidence of these chronic inﬂammatory diseases.
1.Introduction
Fatty acids are hydrocarbon chains with a carboxyl group
at one end and a methyl group at the other. The biological
reactivity of fatty acids is deﬁned by the length of the carbon
chain and by both the number and position of any double
bonds present. While saturated fatty acids do not contain
double bonds within the acyl chain, unsaturated fatty acids
c o n t a i na tl e a s to n ed o u b l eb o n d .W h e nt w oo rm o r ed o u b l e
bonds are present, unsaturated fatty acids are referred to as
PUFA [1]. There are two families of PUFA, and they are
classiﬁed as omega-3 (n-3) and omega-6 (n-6) based on
the location of the last double bond relative to the terminal
methyl end of the molecule [2]. The human body can
produce all but two of the fatty acids it requires. Linoleic acid
(LA, C18:2n-6) (precursor to the n-6 series of fatty acids)
and α-linolenic acid (ALA, C18:3n-3) (precursor to the n-
3 series of fatty acids) are the simplest members of each
family of PUFA and are termed essential fatty acids as the
body cannot synthesise these. PUFA regulate a wide variety
of biological functions, depending on the location of the last
double bond, which range from blood pressure and blood
clotting to the correct development and functioning of the
brain and nervous system [2]. In addition, lipid mediators
generated from long-chain (LC-) PUFA (arachidonic acid
(AA) in the n-6 series and eicosapentaenoic acid (EPA)
and docosahexaenoic acid (DHA) in the n-3 series) have
importantrolesinimmuneregulationandinﬂammation[3].
The main dietary sources of LA include plant oils such as
sunﬂower, saﬄower, and corn oils (Table 1), but they are
also present in cereals, animal fat, and wholegrain bread.
Rich dietary sources of ALA include green leafy vegetables,
ﬂaxseed, and rapeseed oils [2]( Table 1).
Over the last few decades, extreme qualitative nutritional
changes have taken place with increased levels of fatty
acid consumption [4]. Today, industrialised societies are
characterised by an increase in saturated fat, omega 6 PUFA,
and trans fatty acid intake, as well as an overall decrease in
omega-3PUFAintake[5].Fattyacidsnowrepresent28–42%
of total energy consumed by European populations [4, 6],2 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
Table 1: PUFA content of dietary components.
Fat type LA ALA AA EPA + DHA
Saturated
Lard 8600 1000 1070
Butter fat 2300 1400
Coconut oil 1400
Beef tallow 80
Unsaturated
(1) Monounsaturated
Peanut oil 23900
Pecans 20600 1000
Almonds 9860 260
Olive oil 8000 950
Avocado 1970
(2) Polyunsaturated
Omega-6
Saﬄower oil 74000 470
Sunﬂower oil 60200 500
Soybean oil 53400 7600
Corn oil 50000 900
Cotton seed oil 47800 1000
Walnut 34100 6800 590
Brazil nut 24900
Omega-3
Linseed oil 13400 55300
Canola oil 19100 8600
Salmon 440 550 300 1200
Tuna 260 270 280 400
Herring 150 62 37 1700
Trout 74 30 500
Cod 4 2 3 300
Data are expressed as mg/100g edible portion. Data are elaborated from
[13, 14, 18].
Content of fatty acids may vary slightly according to species, sources, and
analytical factors.
whereas, in ancestral nutrition, fatty acid consumption was
only approximately 20–30% of total energy [4, 7, 8]. As a
result of the increased consumption of LA-rich vegetable oils
associatedwiththeWesterndiet,n-6PUFAconsumptionhas
become progressively much higher than that of n-3 PUFA
[9]. Optimal dietary intakes of the n-6:n-3 ratio should
be around 1–4:1. However, according to the nutritional
changes described above in the Western diet, this ratio has
now increased to be within the range of 10:1 to 20:1 [4].
In parallel, there are coinciding increases in the incidence
of diseases involving inﬂammatory processes such as car-
diovascular disease, obesity, IBD, rheumatoid arthritis, and
cancer. Neurodegenerative and psychiatric illnesses such as
AD and depression are other examples [10]. A study carried
out by Hassan and Hanachi, involving 984 Iranian women,
suggested that a good dietary pattern rich in fruits, legumes,
vegetables, cereals, and ﬁsh, rich in n-3 PUFA, can decrease
the likelihood of developing the Metabolic Syndrome [11].
Another study performed in France, involving 912 men,
concluded that a low consumption of ﬁsh rich in n-3 PUFA
is associated with a higher probability of developing the
Metabolic Syndrome [12]. Thus, high intake of n-6 PUFA,
along with low intakes of n-3 PUFA, shifts the physiological
state to one that is proinﬂammatory and prothrombotic
with increases in vasospasm, vasoconstriction, and blood
viscosity and the development of diseases associated with
these conditions.
PUFA play an important role in the composition of all
cell membranes where they maintain homeostasis for correct
membrane protein function and inﬂuence membrane ﬂuid-
ity,thusregulatingcellsignallingprocesses,cellularfunctions
and gene expression [13]. Other functions of PUFA require
their metabolism to more highly unsaturated members of
their family. For example, LA is converted to AA (20:4n-6)
via γ-linolenic acid (GLA, 18:3n-6) and dihomo-γ-linolenic
acid (DGLA, 20:3n-6). By the same set of enzymes, ALA
can be converted to EPA (20:5n-3) and DHA (22:6n-3). The
primary site for PUFA metabolism is the liver; however,
it can also take place in various other tissues [14]. It is
these longer chain metabolites of LA and ALA that are
of major clinical importance within diﬀerent organs such
as the brain, kidney, and liver [15–17]. Cyclooxygenases
(COX) and lipoxygenases (LOX) can convert AA to the
2-series of prostaglandins, the 2-series of thromboxanes,
and the 4-series of leukotrienes. These are very important,
activeandshort-livedhormonestermed“eicosanoids”which
are involved in various pathological processes involving
inﬂammatoryconditionssuchasatherosclerosis,obesity,and
IBD [13].
Since PUFA give rise to a variety of biologically active
compounds which all have important roles in pathological
and physiological processes, a proper understanding is
needed regarding the contribution these active compounds
have on the coinciding increases in inﬂammatory diseases
seen with the disruption of the balance in the ratio of n-6:n-
3 associated with the Western diet.
2. Metabolism of n-6 FattyAcids and
Biosynthesis of Eicosanoids
Linoleic acid can be metabolized to other more unsaturated,
long-chain members of the n-6 family by the insertion of
additional double bonds during consecutive elongation and
desaturation mechanisms (Figure 1). The initial rate limiting
desaturation of LA to GLA is catalysed by the enzyme delta-
6-desaturase (FADS2) [19]. Elongation then takes place to
convert GLA to DGLA, by elongation of very long-chain
fatty acids (ELOVL) 5, and ﬁnally a cycle of elongation and
desaturation by delta-5-desaturase (FADS1) generates AA
[20].
The importance of the FADS2 gene in LC-PUFA synthe-
sis has recently been demonstrated in mice [19, 22]. The ﬁrst
s t u d yb yS t o ﬀel et al. demonstrates that loss of the FADS2
gene abolishes synthesis of LC-PUFA with further down-
stream eﬀects on the COX and LOX pathways, eventually
leading to hypogonadism and sterility of male and female
mice [19]. Further demonstrated by this FADS2 null modelJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 3
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Figure 1: Metabolism of n-6 and n-3 PUFA. The metabolism of PUFA is a complex process involving several enzymes of desaturation,
elongation, and β-oxidation. Shown here is the pathway of both n-6 and n-3 PUFA metabolism to more unsaturated, long-chain members
of each family. Also shown are their respective eicosanoid derivatives. Data elaborated from [21].
was the pivotal role PUFA-substituted phospholipids play
in establishing cell polarity, shown here for tight junctions
of Sertoli cells of the testis and the gap junction network
betweenovarianfolliclecells[19].Stroudetal.demonstrated
impairment of male reproduction and also both dermal and
intestinal ulceration in FADS2 null mice [22].
Elongation of very long-chain fatty acids (ELOVL) 5 is
one of seven mammalian fatty acid condensing enzymes
involved in microsomal fatty acid elongation [20]. ELOVL5
is required for the elongation of GLA to DGLA. Studies
using liver microsomal protein from ELOVL5 null mice
found greater tissue accumulation of GLA and a decrease
in the levels of downstream metabolism products such as
AA for n-6 metabolism and DHA for n-3 metabolism. The
metabolicconsequenceofthisreductionofAAandDHAwas
the activation (or derepression) of sterol regulatory element-
binding protein (SREBP)-1c. Activation of this transcription
factor (as will be discussed in further detail later) in ELOVL5
null mice resulted in the activation of further genes involved
in fatty acid and triglyceride synthesis, which culminated in
the development of hepatic steatosis [20].
There are many other factors involved in the regulation
ofdelta-5-desaturaseanddelta-6-desaturaseenzymeactivity.
For example, decreased activity in both delta-5 and delta-
6 desaturases have been demonstrated in the liver of obese
NAFLD patients [23]. Glucagon, adrenaline, glucocorti-
coids, and thryroxin depress delta-5-desaturase and delta-
6-desaturase activity [24]. Low delta-6-desaturase enzyme
activity was reported in diabetic rats where insulin acts as a
well-knowndelta-6-desaturasestimulator[25].SinceLAand
ALA are metabolized by the same set of enzymes, a natural
competition exists between these two fatty acids, whereby
delta-5-desaturase and delta-6-desaturase will exhibit aﬃn-
ity to metabolize n-3 over n-6 PUFA, provided that they
exist in a ratio of 1:1–4. However, the higher consumption
of LA, as now seen in the Western diet, shows an increase
in the preference of these enzymes to metabolize n-6 PUFA,
leading to AA synthesis, despite the fact that these enzymes
show higher aﬃnity for n-3 PUFA [26]. Supplementation of
the diet with EPA and DHA has been shown to correct this
imbalancebypartiallyreplacingAAfromthecellmembranes
of platelets, erythrocytes, neutrophils, monocytes, and hepa-
tocytes where AA is usually found in high proportions [27].
The intermediates of PUFA metabolism can either be
incorporated into phospholipids or undergo further elon-
gation/desaturation steps. In the n-6 pathway, AA, synthe-
sized from the desaturation of DGLA by delta-5-desaturase
(FADS1), can be further elongated by ELOVL2 to docosate-
traenoicacid(C22:4n-6)ortoitsrespectivesetofeicosanoids
via COX and LOX enzymes. The importance of ELOVL2-
derived PUFA in mammals has recently been demonstrated
in ELOVL2-ablated mice, thus demonstrating the impor-
tance of this elongase enzyme [28]. This study showed the
role ELOVL2 plays in the elongation of C20 and C22 PUFA
in order to produce C24:4n-6 up to C30:5n-6 PUFA in testis,
where they are required for normal spermatogenesis and4 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
fertility [28]. Binding of growth factors and hormones to
membrane receptors leads to activation of phospholipase
A2 which releases AA from the cell membrane where the
free acid can become a substrate for eicosanoid biosynthesis
through the activities of COX and LOX [29]. The eicosanoids
derived from AA are synthesized in larger quantities than
ever before due to increases in dietary intake [4].
Eicosanoids are biologically active lipids and include
prostaglandins (PGs), thromboxanes (TXs), leukotrienes
(LTs), and hydroxyeicosatetraenoic acids (HETEs) which
have all been implicated in various pathological processes
such as inﬂammation and cancer (Table 2)[ 30]. When
they are present in high quantities, they inﬂuence various
metabolic activities besides inﬂammation such as platelet
aggregation, haemorrhage, vasoconstriction, and vasodila-
tion [18]. In general, AA-derived eicosanoids are proin-
ﬂammatory but they have important homeostatic func-
tions in regulating both the promotion and resolution of
inﬂammation in the immune response [31]. In contrast,
it is known that the n-3 PUFA and their LC-derivatives
mostlypromoteanti-inﬂammatoryactivities[32].Inarecent
study involving 250 clinically stable, chronic obstructive
pulmonary disease (COPD) patients, higher intakes of n-3
PUFA were associated with lower proinﬂammatory cytokine
concentrations (e.g., tumour necrosis factor alpha (TNFα))
while higher n-6 PUFA intake was associated with higher
proinﬂammatoryinterleukin-6(IL-6)andC-reactiveprotein
(CRP) concentrations in the diseased state [33]. While
COPD is a complex chronic inﬂammatory condition, it is
interesting to see the association between dietary intake
of n-6 versus n-3 PUFA on serum inﬂammatory markers
associated with the disease [33]. Despite ample evidence
that increased dietary consumption of n-6 PUFA induces a
proinﬂammatory response in the host, it must be reported
that recent studies have also shown the opposite [34, 35].
A recent review has suggested that n-6 PUFA have some
anti-inﬂammatory actions such as those of the n-3 PUFA
[36]. For example, mean serum CRP concentrations tended
to decrease with increased n-6 PUFA consumption in both
Japanese men [34]a n dw o m e n[ 35]. Nevertheless, evidence
of these associations is limited.
Metabolism of AA by the COX enzymes (COX-1, a con-
stitutive enzyme, or COX-2, an inducible enzyme) leads
to the synthesis of the 2-series of prostaglandins: PGE2,
PGI2,PGD 2,andPGF 2α (largelyproducedbymonocytesand
macrophages) and thromboxanes A2 and B2.C o l l e c t i v e l y ,
the prostaglandins and thromboxanes are referred to as
the prostanoids. The synthesis of AA-derived eicosanoids
is, however, dependent on the concentration of DGLA,
as DGLA competes with AA for COX and LOX. When
DGLA is in excess, it inhibits the synthesis of AA-derived
eicosanoids due to its higher aﬃnity for the COX and LOX
enzymes [40]. The activity of 5-LOX metabolises AA to
hydroxylandhydroperoxyderivatives:5-HETEand5-hydro-
peroxyeicosatetraenoic acid (5-HPETE). These derivatives
in turn produce the 4-series of leukotrienes: leukotriene
A4 (LTA4), leukotriene B4 (LTB4), leukotriene C4 (LTC4),
leukotriene D4 (LTD4), and leukotriene E4 (LTE4). Mono-
cytes, macrophages, and neutrophils produce LTB4, while
mast cells, eosinophils and basophils produce LTC4,L T D 4,
and LTE4 [41].
Prostaglandin overproduction has various proinﬂamma-
tory eﬀects. For example, PGI2 and PGE2 exert their acute
inﬂammatory response in arthritis [42, 43]. PGE2 can also
increase its own synthesis through induction of COX-2
leading to the production of the proinﬂammatory cytokine
IL-6 in macrophages [41, 44]. TXB2 is a potent vasoconstric-
tor and platelet activator. LTB4 has many proinﬂammatory
functions, acting as an important activator of neutrophils,
a chemotactic agent for leukocytes, induces release of
lysosomalenzymes,acceleratesreactiveoxygenspecies(ROS)
production, and increases vascular permeability [21]. LTB4
also leads to the production of inﬂammatory cytokines like
TNF-α, interleukin 1 beta (IL-1β) and IL-6 by macrophages
[45]. However, the overall pathophysiological outcome will
depend on the cells present, the nature of the stimulus,
the timing of eicosanoid generation, the concentrations of
diﬀerent eicosanoids generated, and the sensitivity of target
cells and tissues to the eicosanoids generated [1].
In contrast, EPA can also act as a substrate for COX and
LOX enzymes and gives rise to an entirely diﬀerent set of
eicosanoids (Table 2). These are the 3-series prostaglandins
and thromboxanes and the 5-series leukotrienes, which are
considered to be less inﬂammatory or even anti-inﬂamma-
toryin comparison totheeicosanoid familyderived fromAA
[46].
3. How n-6 PUFA-DerivedEicosanoids
Inﬂuence Inﬂammatory Responses
The mode by which prostaglandins and leukotrienes exert
their biological homeostatic and inﬂammatory actions
depends on binding to their respective G-protein coupled
receptors (GPCRs). Speciﬁc GPCRs have been identiﬁed for
all the prostanoids, where there are at least nine known
prostanoid receptor forms in mouse and man [47, 48].
Although most of the prostaglandin GPCRs are localised at
the plasma membrane of platelets, vascular smooth muscle
cells,andmastcells,somearesituatedatthenuclearenvelope
[49]. Four of these receptor subtypes bind PGE2 (EP1–
EP4), two bind PGD2 (DP1 and DP2), and more speciﬁc
receptors bind PGF2α,P G I 2,a n dT X A 2 (FP, IP, and TP,
resp.) [37]. PGE2 and PGI2 are the predominant proinﬂam-
matory prostanoids, and, through their activation of EP2
and IP, respectively, they can increase vascular permeability
and leukocyte inﬁltration. In individuals with asthma, a
bronchial allergen leads to enhanced PGD2 production.
Thus, during asthmatic attacks in humans, PGD2 is released
in large amounts by mast cells [50]. PGD2 can also promote
inﬂammation via DP2 through activation of eosinophils [47,
51].
Four distinct GPCRs for leukotrienes have been charac-
terized. LTB4 interacts with BTL1 and BTL2 through which
important roles in host defence of cells and inﬂammation
are mediated [52]. LTB4 induces leukocyte inﬁltration and
as already mentioned above leads to the release of proin-
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Table 2: Proinﬂammatory eﬀects of n-6 fatty-acid-derived eicosanoids and anti-inﬂammatory eﬀects of the n-3 fatty-acid-derived
eicosanoids.
Proinﬂammatory eﬀects of the n-6 fatty-acid-derived eicosanoids
Arachidonic acid (n-6)
derived eicosanoids Physiological eﬀects Organs or cells
Prostaglandins
PGD2
Bronchoconstriction
Proinﬂammatory
Bronchi
Activation of eosinophils
PGE2
Proarrhythmic
Induces fever
Causes pain
Increases production of IL-6
Vessels
Nociceptor sensory
neurons
PGF2 Bronchoconstriction Bronchi
PGI2
Proarrhythmic Vessels
Causes pain Nociceptor sensory
neurons
Thromboxanes
TXA2
Proaggregation
Vasoconstriction
Bronchoconstriction
Platelets
Vessels
Bronchi
TXB2
Proaggregation
Vasoconstriction
Bronchoconstriction
Platelets
Vessels
Bronchi
Leukotrienes
LTA4
LTB4
Proinﬂammatory
Chemotaxis
Release of reactive oxygen species
Leukocytes
Leukocytes
Granulocytes
LTC4
LTD4
LTE4
Anti-inﬂammatory eﬀects of the n-3 fatty-acid-derived eicosanoids
E P Aa n dD H A( n - 3 )
derived eicosanoids Physiological eﬀects Organs or cells
Prostaglandins
PGD3
PGE3 Antiarrhythmic Vessels
PGF3
PGI3 Antiarrhythmic Vessels
Thromboxanes TXA3 Antiaggregation Platelets
TXB3 Antiaggregation Platelets
Leukotrienes
LTA5
LTB5 Anti-inﬂammatory Leukocytes
LTC5
LTD5
LTE5
Resolvins RVE1
Antiaggregation
Anti-inﬂammatory
Platelets
Dendritic cells
RVD Anti-inﬂammatory
Neuroprotectin NPD1
Anti-inﬂammatory
Antiapoptotic
Decreases oxidative stress
Retina (photoreceptor
cells) and brain
Data elaborated from [21, 37–39].
the colonic mucosa contains 3- to 7-fold higher counts of
cells expressing the 5-LOX pathway, thus increasing the
tissue synthesis of LTB4 [53]. LTC4 and LTD4 can contract
smooth muscle by interacting with two subtypes of cysteinyl
leukotriene receptors, CysLT1 and CysLT2 [54].
The proinﬂammatory eﬀects of the AA-derived pros-
tanoids and leukotrienes have been described [37]. A mecha-
nism has been proposed whereby a coordinated program for
resolution initiates in the ﬁrst few hours after the inﬂam-
matory response. A switch occurs whereby the AA-derived6 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
prostanoids and leukotrienes, which have set the inﬂam-
matory response to begin, undergo further metabolism to
become another generation of eicosanoids derived from AA
termed lipoxins and hence terminate inﬂammation at the
local contained sites [55]. Since these lipoxins are involved
in the resolution of the acute inﬂammation that occurs
as a result of the overproduction of the proinﬂammatory
eicosanoids derived from AA, they are said to have “pro-
resolving” and anti-inﬂammatory functions. These events
coincide with the biosynthesis of resolvins and protectins
from n-3 fatty acids, which act to shorten the period
of neutrophil inﬁltration [55]. However, while the initial
response of the AA-derived eicosanoids to promote inﬂam-
mation is beneﬁcial in one respect, for example, in the
control of blood ﬂow and vessel dilation, the increase in
the ratio of n-6:n-3 PUFA leads to an overall increase
in the production of proinﬂammatory cytokines and an
unnecessary over reactive inﬂammatory response leading
to the pathogenesis of inﬂammatory diseases. In addition,
the decrease in consumption of n-3 PUFA which leads to
a no v e r a l ld e c r e a s ei nr e s o l v i na n dp r o t e c t i np r o d u c t i o ni s
detrimental to the inﬂammatory response as these prod-
ucts, which have the ability to dominate the resolution
phase of inﬂammation, can no longer exert this potential;
thus, the inﬂammatory response cannot be terminated
eﬀectively.
4. n-6 PUFARegulation of
Inﬂammatory GeneExpression
Nuclear receptors are a family of ligand-activated transcrip-
tion factors that either directly or indirectly control various
genes of lipid metabolism and inﬂammatory signalling
[21]. Upon ligand binding, nuclear receptors can undergo
conformational changes which dissociate corepressors and
facilitate recruitment of coactivator proteins to enable tran-
scription activation [21, 56]. LC-PUFA and their eicosanoid
derivatives can act as ligands for these transcription factors
and hence elicit changes in gene expression by governing
the activity of nuclear transcription factors. The regulation
of gene expression by dietary fats is believed to be one of
the greatest factors impacting on the development of certain
diseases of aﬄuence related to the Metabolic Syndrome, such
as hepatic steatosis and NAFLD.
The peroxisome proliferator-activated receptor (PPAR)
family is composed of three proteins: PPARα,P P A R β/δ,
and PPARγ, and, although they each have diﬀerent tissue
distributions, their biological functions overlap [57]. The
PPARs have emerged as important regulators of metabolic
and inﬂammatory signalling, in both metabolic disease and
immunity [57] .T h er o l eP P A R α plays in the regulation
of genes involved in lipid metabolism was ﬁrst identiﬁed
in the early 1990s, on the basis of being a target of the
hypolipidaemic ﬁbrate drugs and other compounds that
induce peroxisome proliferation in rodents [57, 58]. PUFA,
especially those of the n-3 family and their eicosanoid
derivatives, are ligands for the PPARs. The n-3 fatty acids
EPA and DHA have been shown to be more potent as in vivo
activators of PPARα than the n-6 fatty acids [59–62]. Once
PPARs become activated, they form heterodimers with the
retinoid X receptor (RXR) and these dimers then bind to
PPAR responsive elements (PPREs) in target genes to alter
coactivator/corepressor dynamics and induce transcription
[63]. PPARα has recently been shown to exert hypolipi-
daemic eﬀects through activation of skeletal muscle, cardiac
and hepatic genes encoding proteins which are involved
in lipid oxidation [63–65]. Thus, the PPARs, particularly
PPARα, play an important role in insulin sensitization,
atherosclerosis, and metabolic diseases. In the regulation of
inﬂammatory signalling, PPARs inhibit nuclear factor-kappa
B( N F κB) expression.
NFκB, another transcription factor regulated by PUFA,
is found in almost all animal cell types, has a crucial role
in inﬂammatory signalling pathways, and plays a key role
in regulating the immune response to infection. It controls
several cytokines (e.g., IL-1, IL-2, IL-6, IL-12, and TNF-α),
chemokines (e.g., IL-8, monocyte chemoattractant protein-
1), adhesion molecules, and inducible eﬀector enzymes
(e.g., inducible nitric oxide synthase and COX-2) [2]. NFκB
becomes activated as a result of a signalling cascade triggered
by extracellular inﬂammatory stimuli (such as free radicals,
bacterial or viral antigens), which involves phosphorylation
of an inhibitory subunit of NFκB( I κB), which in turn
allows the translocation of the remaining NFκB dimer to
the nucleus, with the result of an increase in expression
of inﬂammatory genes [66]. Since the n-3 LC-PUFA show
anti-inﬂammatory action, they inhibit NFκBa c t i v i t y .A sa n
example, both EPA and DHA have been shown to block
the activity of NFκB through decreased degradation of IκB,
in human monocytes and human THP-1 monocyte-derived
macrophages [67, 68]. However, this eﬀect is not observed
to the same extent with n-6 LC-PUFA, due to potency in the
inhibition of NFκB[ 69]. Interestingly, 5-LOX, the enzyme
which converts AA to the 4-series leukotrienes and 5-HETE,
translocates into the nucleus in association with NFκB[ 70,
71].
SREBP-1c is a transcription factor required for the
insulin-mediated induction of hepatic fatty acid and triglyc-
eride synthesis. Responsive targets in mammalian cells in-
clude genes of fatty acid metabolism, such as fatty acid
synthase (FAS), and its expression is most commonly found
in high levels in macrophages, liver, white adipose tissue,
adrenal glands, and the brain of both mice and humans
[72]. PUFA have the ability to modulate SREBP-1c activity
and expression. For example, n-3 LC-PUFA have been
shown to suppress SREBP-1c gene expression and so inhibit
transcription of lipogenic and hepatic genes involved in lipid
biosynthesis [73, 74]. Studies have shown that a decrease
in hepatic SREBP-1c leads to a decrease in hepatic FAS,
thus lowering lipid accumulation within the liver [75–
77]. However, the n-3 PUFA are more potent inhibitors
of SREBP-1c, than the n-6 PUFA [21], and this will be
discussed in more detail further on. More recently, the liver
Xr e c e p t o r s( L X R - α and -β) have been shown to play a
major role in lipogenesis through regulation of transcription
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that the downregulation of SREBP-1c transcription by n-3
PUFA results from attenuated transactivation of the ligand-
activated nuclear receptor LXR-α [77]. A more recent study
in mice fed an n-3 PUFA depleted diet showed increased
activation of SREBP-1c and related pathways which was
consistent with increased LXR activity, thus highlighting
the importance of n-3 PUFA depletion related to lipid
accumulation in the liver [78]. However, in another study by
Pawar et al., ﬁsh oil fed rats showed a suppression of hepatic
SREBP-1c target genes, but no change in expression of genes
directlyregulatedbyLXR[79].InhibitionofLXRmayalsobe
an indirect eﬀect of PUFA stimulation of PPAR transcription
factors [21]. Cross-talk between PPARα and LXR via SREBP-
1c has been reported, whereby overexpression of PPARα
inhibitedLXR-inducedSREBP-1cpromoteractivity,through
a reduction of LXR binding to its activator, RXR [80]. Both
n-6 and n-3 PUFA are often interchangeable in regulating
gene expression. However, it is well known that n-3 PUFA
are more potent ligands to these nuclear receptors than n-
6P U F A[ 21]. Through n-3 PUFA-mediated activation of
PPARα and inhibition of SREBP-1c, lipid biosynthesis can be
reduced and lipid degradation can be increased [21, 29].
By targeting the transcription of various nuclear recep-
torsinvolvedinregulatinglipogenicgeneexpressionthrough
dietary fatty acids, prevention of certain diseases related
to the Metabolic Syndrome, such as hepatic steatosis and
NAFLD, can be reduced in the future. The contribution n-
6 PUFA make to the development of liver disease due to the
increased consumption of LA-rich foods and the decreased
consumption of ALA rich foods is phenomenal and will
be discussed in further detail. Already discussed are the
positive contributions of n-3 PUFA in the prevention of
lipid biosynthesis in various organs, such as the liver, for
example, through the activation of PPARα and inhibition
of NFκB and SREBP-1c. However, since these n-3 PUFA
are more potent ligands for these nuclear receptors and
Western diets overall consumption of n-6:n-3 has increased
dramatically over the last 50 years in particular, what now
becomes the fate of the these nuclear receptors and how
have our dietary changes impacted upon our health status
through regulation of inﬂammatory gene expression? More
importantly, determination of the molecular and cellular
mechanisms regulated by PUFA may help identify novel sites
for pharmacological intervention.
5. n-6 PUFA Contribution to Chronic
Inﬂammatory Conditions in Humans
Clinical studies indicate that inﬂammation is at the base
of many diseases including NAFLD, cardiovascular disease,
atherosclerosis, IBD, and neurodegenerative diseases such
as AD (Figure 2). The contribution of n-6 PUFA to these
inﬂammatory conditions will be reviewed below with a par-
ticular focus on NAFLD.
5.1. Nonalcoholic Fatty Liver Disease (NAFLD). NAFLD is
often described as the hepatic component of the Metabolic
Syndrome and is rapidly becoming a serious public health
Proinﬂammatory cytokine production
Anti-inﬂammatory cytokine production
SREBP-1c
NAFLD, CVD, IBD, rheumatoid
arthritis, AD
AA-derived TXA2, PGE2, LTB4, LTC4-LTE4
EPA/DHA-derived TXA3, PGE3, LTB5, LTC5-LTE5
NFκBP P A R α
n-6
n-3
Figure 2: Eﬀects of unbalanced n-6:n-3 dietary fatty acid intake
on development of various diseases of inﬂammation. Dietary
imbalance in the consumption of n-6 and n-3 PUFA, representative
of the Western diet. Greater consumption of n-6 PUFA leads to an
increase in their metabolism to their LC-PUFA derivatives (AA).
Decreases in n-3 PUFA consumption leads to a decrease in their
metabolismtotheirLC-PUFAderivatives(EPA/DHA).Theincrease
in AA in cell membrane phospholipids leads to an increase in
COX and LOX enzyme production of AA-derived eicosanoids and
a decrease in EPA/DHA-derived eicosanoids, leading to an increase
in inﬂammation and proinﬂammatory cytokine production. This
in turn leads to a decrease in PPARα gene expression, while there
is an increase in both SREBP-1c and NFκB gene expression. This
change in gene expression can also cause an increase in lipogenesis,
as well as increasing inﬂammation. The result is an increase in
various diseases of inﬂammation, some of which are highlighted in
the ﬁgure.
problem [81]. The range of liver damage associated with
NAFLD begins with steatosis and can often persist to
further steatohepatitis (NASH), advanced ﬁbrosis and cir-
rhosis [82]. NAFLD itself is an independent risk factor
for cardiovascular disease (CVD). Occurrence of NAFLD
is much higher in subgroups of the population with
obesity, Metabolic Syndrome, and type 2 diabetes, whereby8 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
prevalence in developing the disease for those with type 2
diabetes may be as high as 70% [82, 83]. Both nutritional
factors and alterations in lipid metabolism of the liver are
the primary metabolic abnormalities which lead to hepatic
steatosis [84].
Theroleofn-3LC-PUFAasapotentialtherapeutictarget
in the pathogenesis of NAFLD has recently been demon-
strated [85]. Within the liver, n-3 LC-PUFA presence is
associated with an increased ability to direct fatty acids away
from triacylglycerol storage and to enhance their oxidation.
However, n-3 LC-PUFA levels are decreased in the hepatic
tissue of patients with NAFLD [86, 87]. Depletion of n-3 LC-
PUFAwithintheliversofNAFLDpatientsisamajorproblem
as liver fatty acids now become directed away from oxidation
and secretion and instead towards triacylglycerol storage. In
addition, a higher n-6:n-3 LC-PUFA ratio within the liver
of NAFLD patients may contribute to the development of
fatty liver due to a derangement in the capacity to regulate
liver lipid metabolism [86] .Ar e c e n tc o m p a r a t i v er e v i e w
also demonstrated various mechanisms through which con-
sumption of ﬁsh oil has been beneﬁcial in the alleviation of
NAFLDsuchas(i)decreasedplasmanonesteriﬁedfattyacids
(NEFA) concentrations; (ii) decreased de novo lipogenesis,
very low-density lipoprotein (VLDL) export, and plasma
triglycerideconcentrations;(iii)decreasedadipocytesizeand
visceral fat content [88]. The mechanisms which lead to
the development of fatty liver, such as impaired fatty acid
oxidation and increased de novo fatty acid synthesis, are
regulated by hepatic gene transcription.
n-3 LC-PUFA regulate lipid metabolism in the liver by
acting as ligand activators of the transcription factor PPARα.
Activation of PPARα results in the upregulation of genes
which are involved in fatty acid and lipid metabolism and
which stimulate fatty acid oxidation [17, 89]. In two separate
studies employing murine models of NASH, administration
of a PPARα agonist prevented steatohepatitis and reversed
the established disease [90, 91].
VLDL is a type of lipoprotein made by the liver from
triglycerides, cholesterols, and apolipoproteins. Within the
bloodstream, VLDL transports cholesterol from the liver,
thus enabling fats to move within the bloodstream, and
it is here that VLDL itself also acts as a precursor to
low-density lipoprotein (LDL), often referred to as “bad
cholesterol.” PPARα activation increases the secretion of
apoliopoprotein B-100 (apo B-100), which is the main
structural protein of VLDL, and upregulates the expression
of liver fatty acid binding protein (LFABP) which is essential
for the secretion of apo B-100 [92, 93]. Since n-3 LC-
PUFA upregulate PPARα, hepatic fatty acid oxidation has
the potential to occur within the liver, and, since more apo
B-100 is secreted out of the liver, less VLDL is synthesized,
with the result of less of this harmful cholesterol entering
the bloodstream, where the downstream further eﬀects
on the development of atherosclerosis are attenuated [94].
However, with the reduced availability of n-3 LC-PUFA from
dietary intake and the increases in n-6 PUFA consumption,
PPARα does not become activated to its full potential.
This results in PUFA favouring fatty acid and triglyceride
synthesis over fatty acid degradation. As demonstrated by
PPARα−/− mice, rates in their ability to oxidise fatty acids
are decreased during periods of food deprivation; thus,
theydevelopcharacteristicsofadult-onsetdiabetesincluding
fatty livers, elevated blood triglyceride concentrations, and
hyperglycemia [95].
n-3 LC-PUFA are also involved in the negative regulation
of the transcription factor SREBP-1c within the liver, thus
acting as inhibitors in the expression of lipogenic genes such
as FAS [73]. The eﬀect n-3 LC-PUFA have on SREBP-1c is
to reduce endogenous lipid production and accumulation of
triglyceridesintheliver[96],andthisisachievedbyreducing
the amount of mature SREBP-1c available for de novo
lipogenesis within the nucleus [97]. Therefore, depletion of
n-3 LC-PUFA and an increase in the ratio of n-6:n-3 LC-
PUFA in the liver of NAFLD patients results in fatty acid
and triacylglycerol synthesis over oxidation, again leading
to fatty liver. A recent study by Pachikian et al. using mice
fed a depleted n-3 PUFA diet showed increases in hepatic
activation of SREBP-1c leading to increased lipogenesis,
contributing to hepatic steatosis [78]. This is consistent with
a previous study in rats fed an n-3 PUFA-depleted diet
whereby hepatic accumulation of triglycerides and esteriﬁed
cholesterol led to both macro-and microvesicular steatosis
caused by changes in the fatty acid pattern that resulted from
n-3 PUFA depletion [98].
Another mechanism involved in the depletion of n-
3 LC-PUFA from the liver of obese NAFLD patients and
which further exacerbates the disease progression is the
decreased liver fatty acid delta-5 and delta-6 activity in
these patients [23]. Impairment of these enzymes aﬀects the
desaturation and elongation pathways of LA and ALA, which
are required for the synthesis of their LC-PUFA derivatives
within the liver [99]. Decreased activity in both delta-5
and delta-6 desaturases has been demonstrated in the liver
of obese NAFLD patients [23]. This may be attributed to
the lower intake of ALA (n-3 precursor), the imbalance
in the n-6:n-3 LC-PUFA ratio which occurs in the liver
and higher consumption of trans isomers (18:1, n-9 trans)
inhibiting delta-6 desaturase [86]. The depletion of n-3 LC-
PUFA within the liver of these patients resulting from the
decrease in delta-5 and delta-6 desaturase activity may lead
to further development of steatosis by altering the activity of
PPARα and SREBP-1c [23]. This will determine a metabolic
imbalance favouring lipogenesis over fatty acid oxidation
since n-3 LC-PUFA depletion induces SREBP-1c expression
and upregulation of lipogenic genes [84]. In general, it is
also understood that the adipose tissue acts as a suitable
biomarker for dietary fatty acid intake. Considering that
in NAFLD, there is an enhancement in n-6 adipose tissue
content and a signiﬁcant decrease in n-3 adipose tissue
content, this suggests that while there is an adequate amount
of n-6 fatty acids for metabolism within the liver, n-3 fatty
acids cannot be metabolized to the same extent due to
inadequate dietary intake. Also, decreased dietary intake of
n-3 PUFA constitutes a limiting factor for the production
of n-3 LC-PUFA in liver lipids of NAFLD patients, resulting
from the competition between the two metabolic pathways
(Figure 1), particularly at the desaturation steps [86]. Thus,
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PUFA and an excess intake of n-6 PUFA leads to defective
desaturation of PUFA [86].
Oxidative stress caused by the accumulation of liver tri-
glycerides and insulin resistance are major contributors in
the pathogenesis of NAFLD [100]. Both oxidative stress
and mitochondrial dysfunction are often associated with
the increased production of ROS and proinﬂammatory
cytokines related to NAFLD [82]. Recent human studies
have described a strong association between the severity of
NASH and the degree of oxidative stress [100–102]. The
increased prooxidant activity associated with oxidative stress
leads to elevation in hepatic lipid peroxidation status. Lipid
peroxidation can also cause immunological dysfunction,
which could lead to the development of hepatic ﬁbrogenesis
[82]. This could potentially lead to an increase in the release
of 4-hydroxy-20-nonenal (HNE), which can bind hepatocyte
proteins forming new antigens and therefore provoking a
harmful immunological response [82]. For example, Seki
et al. reported a correlation between hepatic expression of
HNE and the degree of severity of necroinﬂammation and
ﬁbrosis [103]. Oxidative stress associated with NAFLD has
also been shown to increase production of proinﬂammatory
cytokines. This hepatotoxicity associated with the produc-
tion of inﬂammatory cytokines induced through oxidative
stress may indirectly activate transcription factors such as
NFκB. The accumulation of NEFAs within hepatocytes of
NAFLD patients is another source of NFκBa c t i v a t i o n[ 104].
Oxidative stress and changes in dietary intake trends may
contribute to low hepatic LC-PUFA [105]. The increase in
lipid peroxidation associated with NAFLD, as discussed, may
contribute to the decrease in LC-PUFA, as they are par-
ticularly susceptible to lipid peroxidation [105, 106]. Thus,
oxidative stress-dependent lipid peroxidation may represent
an alternative mechanism to liver n-3 LC-PUFA depletion in
NAFLD [99] ;s i n c eP U F Aa r em o r es u s c e p t i b l et op e r o x i d a -
tion and the greater availability of n-6 LC-PUFA in the livers
of NAFLD patients results in enhanced peroxidation of these
LA derived LC-PUFA into their eicosanoid derivatives [99].
For example, LTB4, an AA-derived eicosanoid, is involved in
acceleration of ROS production. The increased production
of proinﬂammatory cytokines and eicosanoids, produced
from n-6 PUFA metabolism, cause enhanced liver Kupﬀer
cellproductionofinﬂammatorycytokinescausingactivation
of NFκB, further exacerbating systemic and hepatic insulin
resistance with worsening inﬂammation and ﬁbrosis [82].
Insulin resistance as seen in NAFLD may be related to
the depletion in n-3 LC-PUFA because they are expected
to modify membrane-mediated processes such as insulin
signalling [107].
In summary, the depletion of n-3 LC-PUFA, the decrease
in the ratio of product/precursors of LC-PUFA, the increase
in n-6 PUFA, and the increase in n-6 LC-PUFA derived
eicosanoid production within the liver all contribute to the
development of NAFLD and related pathophysiologies such
as insulin resistance. Recently, the relationship between the
n-6:n-3 PUFA ratio within the liver and severity of steatosis
was demonstrated [108]. In this study, patients with NAFLD
showed signiﬁcant correlation between the n-6:n-3 PUFA
ratio and the quantity of hepatic triglycerides, as a marker of
the severity of hepatic steatosis [108]. Defective desaturation
of PUFA due to inadequate intake of n-3 PUFA, and a higher
intake of n-6 PUFA further enhances the contribution of
desaturase inhibition in NAFLD.
5.2. Other Inﬂammatory Conditions Involving n-6 PUFA
5.2.1. Cardiovascular Disease and Atherosclerosis. Atheroscle-
rosis is now considered a “systemic disease” characterised
by low-grade arterial inﬂammatory lesions that can mature
along with disease progression [109]. It is the underlying
cause of coronary heart disease (CHD), and abnormalities
in the metabolism of essential fatty acids that are charac-
teristic of the associated risk factors [110]. Under normal
physiological conditions, healthy endothelial cells synthesise
and release adequate amounts of NO, PGI2,a n dP G E 1,
maintaining a downstream balance between pro- and anti-
inﬂammatory molecules. However, in atherosclerosis, this
balance becomes disrupted, leaning towards an increase in
the production of proinﬂammatory cytokines such as IL-1,
IL-2, IL-6 and TNF-α, resulting in the further progression
of the disease [110]. These proinﬂammatory cytokines can
induce oxidative stress by enhancing the production of ROS
by monocytes, macrophages, and leukocytes. Since PUFA
and their eicosanoid derivatives modulate inﬂammation,
they play a signiﬁcant role in this disease [26]. Decreases
in ALA-derived LC-PUFA such as EPA and DHA seen in
endothelial cell PUFA deﬁciency, increases the production of
proinﬂammatory cytokines and free radicals which results in
the development of insulin resistance [26]. As an example,
early studies in Greenland Eskimos, a population consuming
a high-fat diet, but rich in n-3 PUFA, showed that ingestion
of EPA and DHA led to decreases in the mortality rate from
CVD [111]. Similarly, Japanese populations eat more ﬁsh
than North Americans and present a lower rate of acute
myocardial infarction and atherosclerosis [112, 113]. Other
later studies have further demonstrated strong associations
between n-3 PUFA intake and decreased risks of CVD [114–
116].
The role of n-6 PUFA in CVD is much more complex
than the role of n-3 PUFA. PGE2,P G F 2α,T X A 2,a n dL T sp r o -
duced from AA metabolism are proinﬂammatory [110].
TXA2 acts as a potent vasoconstrictor and powerful activator
of platelet aggregation [117]. Studies have shown that TXA2
promotes the initiation and progression of atherosclerosis by
regulating platelet activation and leukocyte-endothelial cell
interactions [118]. LTB4 acts as a potent chemotactic agent,
inducing the generation of ROS, activating neutrophils, and
inducing the aggregation and adhesion of leukocytes to the
vascular endothelium [110]. The leukotrienes LTC4,L T D 4,
and LTE4 induce vasoconstriction and bronchospasm [110].
Since AA is derived from LA, a reduction of LA intakes
will reduce tissue AA content, which in turn will reduce any
inﬂammatory potential and therefore lower the risk for CVD
[119]. There are many other lines of evidence that link LA
with atherosclerosis. Endothelial dysfunction (ED) is a char-
acteristic of early-state atherosclerosis common in patients
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by Simopoulos reported that diets enriched in LA increase
the LA content of LDL and its susceptibility to oxidation,
whereby oxidative modiﬁcation increases the atherogenicity
of LDL cholesterol [121]. Studies have also shown that in
patients with type 2 diabetes susceptible of developing ED,
there are substantial increases in LA concentrations in all
LDL subfractions [122]. Cellular oxidative stress associated
with LA oxidation of LDL and LA mediated ED is a critical
signal transduction pathway involved in NFκB activation,
whereby NFκB is critical for the expression of inﬂammatory
genes associated with ED [120]. The susceptibility of LDL to
oxidationbyLAanditsassociatedmetabolitesislinkedtothe
severity of coronary atherosclerosis development [121, 123].
Despite the evidence to suggest that n-6 PUFA consumption
increases the risk of developing CVD, recent evidence has
suggested that both LA and ALA have the ability to prevent
CVD [34]. In this study, LA signiﬁcantly reduced levels
of CRP, an inﬂammatory marker, upregulated in CVD in
Japanese men [34]. However, other evidence to suggest that
n-6 PUFA have an anti-inﬂammatory eﬀect when consumed
in such high quantities, such as that seen in the Western diet,
is limited.
Since it has been proposed that diets high in LA reduce
ALA metabolism [124] and since ALA metabolites such as
EPA/DHA have been shown to reduce mortality rates from
CVD[111–113],thebalanceofn-6ton-3PUFAisimportant
in the prevention of atherosclerosis and CVD.
5.2.2. Inﬂammatory Bowel Disease. IBD is classiﬁed as a
group of chronic systemically natured diseases of unclear
pathology which cause inﬂammation of the digestive tract,
including Crohn’s disease (CD) and ulcerative colitis (UC)
[125]. While environmental factors indeed play a signiﬁcant
role in the etiology of the disease, more recent attention
has been placed on various dietary and nutritional factors,
speciﬁcallythelipidcomponentsofthedietastriggersofIBD
[125, 126]. It is diﬃcult to suggest that dietary inﬂuences or
supplementation can reduce the incidence of IBD or impact
beneﬁcially (through anti-inﬂammatory eﬀects) upon the
disease progression since, like many chronic diseases, IBD is
multifactorial.Despitethis,lowerprevalenceofIBDhasbeen
observed with consumption of diets rich in n-3 LC-PUFA
derived from ﬁsh oils, such as that seen of the Greenland
Eskimos [127, 128]. It has also been reported that patients
of IBD who supplement their diets with n-3 PUFA show
anti-inﬂammatory actions, with decreased production of
LTB4 by neutrophils and colonic mucosa, resulting from
incorporation of the n-3 PUFA into the gut mucosal tissue
[129, 130]. A recent study using IL-10 knockout mice
(mice that spontaneously develop colitis) demonstrated
signiﬁcantly reduced colonic inﬂammation when fed n-3
P U F A - r i c hﬁ s ho i la sc o m p a r e dw i t hm i c et h a tw e r ef e dn -
6P U F A - r i c hc o r no i l[ 131]. In Japan, increased reports in
the incidence of IBD correlate with the increased dietary
intake of n-6 PUFA [132, 133]. Importantly, while n-3 PUFA
show decreased production of LTB4 by neutrophils and
colonic mucosa [129, 130], metabolism of AA increases the
production of LTB4 within the inﬂamed intestinal mucosa
of IBD [134]. A more recent report demonstrated abnormal
prevalence of the enzymes that coordinate to generate LTB4
from membrane-derived AA in active IBD biopsies [53]. The
recruitment of neutrophils and other leukocytes to the IBD
gut mucosa seen with colonic injury may be a direct result of
theincreasedabilitytogenerateLTB4 fromAA[53].Itisclear
from the literature that n-3 PUFA have a positive eﬀect on
reducing the risk of IBD [135–137]. The situation is less clear
for n-6 PUFA, although the proinﬂammatory eicosanoids
derived from AA have been shown to play a crucial role in
the pathogenesis of all these related inﬂammatory disorders.
As n-3 PUFA have been shown to alleviate the progression
of IBD, while n-6 PUFA have been implicated in the origin
of IBD, the importance of a balance in the ratio of n-6:n-3
PUFA in today’s dietary regime is highlighted.
5.2.3. Rheumatoid Arthritis. Rheumatoid arthritis is a long-
term disease that leads to inﬂammation of the joints and
surrounding tissues, causing pain, swelling, and impaired
function. It is characterised by inﬁltration of T-lymphocytes,
macrophages, and plasma cells into the synovium, with the
initiation of a chronic inﬂammatory state that involves the
overproduction of proinﬂammatory cytokines [138]. Studies
have shown that AA-derived eicosanoids, PGE2,a n dP G I 2
play a role in the pathogenesis of rheumatoid arthritis
[42, 139]. PGI receptor-deﬁcient (IP−/−)m i c es u b j e c t e dt o
collagen-induced arthritis (CIA) showed a signiﬁcant reduc-
tion in arthritic scores and reduction in IL-1β and IL-6 levels
in the arthritic paws [139]. Inhibition of both PGE receptors
(EP2 and EP4) suppressed inﬂammatory events and arthritis
in CIA. These results suggest that both PGE2 and PGI2
participateinrheumatoidarthritis.Supplementationwithn-
3 PUFA has been demonstrated to modulate the activity of
inﬂammatory factors that cause cartilage destruction during
arthritis [138, 140]. Moreover, decreasing n-6 PUFA intake
(especiallyAA)downtolessthan90mg/daythroughananti-
inﬂammatory lactovegetarian (versus normal Western) diet
was shown to improve the clinical symptoms associated with
rheumatoid arthritis [141].
5.2.4. Alzheimer’s Disease. AD is the most common form of
dementia in the elderly, clinically characterised by memory
dysfunction, loss of lexical access, spatial and temporal
disorientation, and impaired judgement [10]. The patho-
genesis of AD is extremely complex, with genetic factors,
education, and lifestyle all playing crucial roles in disease
onset. However, a poor understanding of the pathogenesis
of AD means that there are no curative treatments yet
available. Recently, much interest has been shown in the
role of diet in both the pathogenesis and prevention of
this disease. The role of n-6 PUFA and oxidised eicosanoid
derivatives of n-6 PUFA have recently been reviewed as
contributing to β-amyloid deposition, a hallmark of AD
onset and progression [142, 143]. AA is distributed in several
diﬀerent cell types in both the grey and white matter in
the brain [10]. The role AA plays in oxidative stress and
lipid peroxidation has already been discussed in relation to
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hasalsobeensuggestedtoplayaroleinAD,thussuggestinga
role of AA and lipid oxidation products (eicosanoids) in the
onsetandprogressionofthedisease[144,145].Furthermore,
theenhancedconsumptionofn-6PUFAleadstoanexcessive
production of the proinﬂammatory cytokines derived from
AA through COX and LOX enzymatic activity which lead
to brain damage [146, 147]. As an example, a study using
transgenic mice with memory impairment and β-amyloid
deposition, fed a diet poor in n-3 PUFA but rich in n-6
PUFA, showed that they were found to have a signiﬁcant
decrease in the postsynaptic receptor complex in the brain
which regulates memory and learning and a net potentiation
of programmed cell death [148]. In contrast, n-3 PUFA may
play a role in the prevention of AD. Studies have shown
that DHA provides support to learning and memory events
in animal models of AD and protection against the disease
[149–151]. Another recent epidemiological study indicated a
relationship between higher ﬁsh consumption and improved
cognitive function in later life [152]. Both DHA and EPA
have been shown to competitively counteract the production
of proinﬂammatory eicosanoids derived from n-6 PUFA in
the brain of AD patients [153]. The neuroprotective role
of EPA has been demonstrated since EPA competes with
AA for incorporation into cell membrane phospholipids
and for oxidation by the COX enzyme, thus exerting anti-
inﬂammatory actions. The resulting production of anti-
inﬂammatoryPGE3 mightresultindecreasedlevelsofproin-
ﬂammatory PGE2 [154]. The balance between the n-6:n-3
PUFA ratio may therefore play a crucial role in the onset of
AD. A recent study showed that a lower n-6:n-3 PUFA ratio
was associated with a lower incidence of dementia, especially
indepressedpatients[155].Furthermore,wehavepreviously
demonstrated in patients with major depression, increases
in plasma AA and IL-6 associated with inﬂammation [156].
Therefore, a dietary pattern consisting of lower n-6 PUFA
and higher n-3 PUFA or a more balanced n-6:n-3 PUFA
ratio may be therapeutic in the pathogenesis of AD.
6. Conclusion
Increases in the ratio of n-6:n-3 PUFA, characteristic of the
Western diet, could potentiate inﬂammatory processes and
consequently predispose to or exacerbate many inﬂamma-
tory diseases. The change in ratio and increase in n-6 PUFA
consumption change the production of important mediators
and regulators of inﬂammation and immune responses
towards a proinﬂammatory proﬁle. Chronic conditions such
as CVD, diabetes, obesity, rheumatoid arthritis, and IBD
are all associated with increased production of PGE2,L T B 4,
TXA2,I L - 1 β,I L - 6 ,a n dT N F - α, whereby the production
of these factors increases with increased dietary intake of
n-6 PUFA and decreased dietary intake of n-3 PUFA. In
conclusion, the unbalanced dietary consumption of n-6:n-
3 PUFA is detrimental to human health, and so the impact of
dietarysupplementationwithn-3PUFAuponthealleviation
of inﬂammatory diseases, more speciﬁcally, NAFLD needs to
be more thoroughly investigated.
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